Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

BACKGROUND: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing pain. We aimed to explore the body composition an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Endocrinol Metab
Hlavní autoři: Brener, Avivit, Lebenthal, Yael, Cleper, Roxana, Kapusta, Livia, Zeitlin, Leonid
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970173/
https://ncbi.nlm.nih.gov/pubmed/33796255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20420188211001150
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky